Nurse Practitioners Are a Touchstone in Lung Cancer Management
October 14th 2021Communication and education of a patient with lung cancer and their family is only part of a nurse practitioner’s responsibility. Moreover, they often represent the primary point of contact for a patient when it comes to their diagnostic workup, treatment follow-up, and symptom management.
Molecular Testing Is Critical With New Targets, Novel Therapies, and Earlier Intervention in NSCLC
October 7th 2021David R. Gandara, highlights key data regarding the earlier integration of targeted therapy in NSCLC, the growing role of molecular testing with tissue and liquid biopsy, and the importance of incorporating a multidisciplinary approach to patient care in the paradigm.
Molecular Testing and Multidisciplinary Care Is A Necessity in Metastatic NSCLC
October 1st 2021Although adjuvant targeted therapy options are reserved for patients with EGFR-mutated non–small cell lung cancer, molecular testing is a critical step in the treatment of all patients with metastatic disease, where multiple driver mutations are associated with FDA-approved therapeutics.
Biomarker Discovery and Testing Are Key to Improving Care for Early-Stage Resectable NSCLC
September 1st 2021Jay M. Lee, MD, discusses the implications of the ADAURA trial in early-stage resectable NSCLC, the importance of molecular testing, and the need for a multidisciplinary approach in this population.
Overcoming Treatment Barriers With Adjuvant Durvalumab in Unresectable Stage III NSCLC
August 4th 2021Benjamin H. Kann, MD, discusses the significance of the PACIFIC trial in patients with stage III NSCLC, existing barriers to treatment, and shared strategies to overcome common challenges faced in clinical practice.
Providing Nursing Insight Into the Management of irAEs in Lung Cancer
May 4th 2021Marianne Davies, NP, DNP, MSN, BSN, discussed the potential severity of immune-related adverse effects and detailed recommended management strategies for patients receiving checkpoint inhibitors, especially in lung cancer.
Molecular Testing Results Are Critical Amid an Expanding Targeted Therapy Paradigm in Advanced NSCLC
May 3rd 2021Julia K. Rotow, MD, discusses how she approaches molecularly testing in patients with liquid- and tissue-based biopsies, the importance of waiting to initiate immunotherapy until a patient’s molecular testing results are confirmed, and other nuances that she considers when treating patients with advanced non–small cell lung cancer.
Research Efforts Mount With Immunotherapy in Advanced NSCLC
May 3rd 2021Christopher G. Azzoli, MD, discusses the importance of identifying molecular aberrations prior to starting a patient with advanced non–small cell lung cancer on immunotherapy, ongoing research aimed at furthering the immunotherapy paradigm, and explained why novel biomarkers of response to immunotherapy are needed.